OSA logo

ProSomnus Common Stock (OSA) Stock

Profile

Sector:

Healthcare

Country:

United States

IPO:

28 July 2021

Indexes:

Not included

Description:

ProSomnus is a company that specializes in creating innovative oral appliances for sleep apnea treatment. Their products help improve sleep quality by keeping airways open during sleep, offering a comfortable alternative to traditional CPAP machines. ProSomnus aims to enhance patient health and well-being through better sleep solutions.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

22 Jan '24 Alliance Global Partners
Buy
10 Nov '23 Craig-Hallum
Hold
26 Sept '23 Roth MKM
Buy
18 Apr '23 Roth MKM
Buy
03 Apr '23 Craig-Hallum
Buy

Screeners with OSA included

No data

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Similar stocks

Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
Adtran's Oscilloquartz high-performance optical cesium technology integrated in Swiss timescale infrastructure at METAS
OSA
businesswire.com04 November 2024

BERN, Switzerland--(BUSINESS WIRE)-- #5G--Adtran today announced that Switzerland's Federal Institute of Metrology METAS has successfully deployed its OSA 3300 HP, improving national timekeeping performance and supporting critical scientific research. As the industry's first high-performance optical cesium atomic clock, the OSA 3300 HP sets new standards for accuracy and stability, while assuring 10 years of operation. It also strengthens Switzerland's contribution to Universal Time Coordinated (UTC).

Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolution
OSA
prnewswire.com21 June 2024

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour) In a key secondary endpoint from two clinical studies, 43.0% and 51.5% of participants taking tirzepatide at the highest dose reached the criteria for disease resolution as defined by apnea-hypopnea index and Epworth Sleepiness Scale measures Lilly submitted tirzepatide for the treatment of moderate-to-severe OSA and obesity to the U.S. Food and Drug Administration (FDA) and will initiate submissions for other global regulatory agencies in the coming weeks INDIANAPOLIS , June 21, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced detailed results from the SURMOUNT-OSA phase 3 clinical trials evaluating tirzepatide injection (10 mg or 15 mg) for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, with and without positive airway pressure (PAP) therapy. In both studies, tirzepatide achieved all primary and key secondary endpoints for both the efficacyi and treatment-regimenii estimands and demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo.

Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks
OSA
businesswire.com13 June 2024

HUNTSVILLE, Ala.--(BUSINESS WIRE)-- #5G--Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran's Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific res.

ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript
OSA
Seeking Alpha27 March 2024

ProSomnus, Inc. (OSA) Q4 2023 Earnings Call Transcript

FAQ

  • What is the primary business of ProSomnus Common Stock?
  • What is the ticker symbol for ProSomnus Common Stock?
  • Does ProSomnus Common Stock pay dividends?
  • What sector is ProSomnus Common Stock in?
  • What industry is ProSomnus Common Stock in?
  • What country is ProSomnus Common Stock based in?
  • When did ProSomnus Common Stock go public?
  • Is ProSomnus Common Stock in the S&P 500?
  • Is ProSomnus Common Stock in the NASDAQ 100?
  • Is ProSomnus Common Stock in the Dow Jones?
  • When was ProSomnus Common Stock's last earnings report?
  • When does ProSomnus Common Stock report earnings?
  • Should I buy ProSomnus Common Stock stock now?

What is the primary business of ProSomnus Common Stock?

ProSomnus is a company that specializes in creating innovative oral appliances for sleep apnea treatment. Their products help improve sleep quality by keeping airways open during sleep, offering a comfortable alternative to traditional CPAP machines. ProSomnus aims to enhance patient health and well-being through better sleep solutions.

What is the ticker symbol for ProSomnus Common Stock?

The ticker symbol for ProSomnus Common Stock is NASDAQ:OSA

Does ProSomnus Common Stock pay dividends?

No, ProSomnus Common Stock does not pay dividends

What sector is ProSomnus Common Stock in?

ProSomnus Common Stock is in the Healthcare sector

What industry is ProSomnus Common Stock in?

ProSomnus Common Stock is in the Medical Devices industry

What country is ProSomnus Common Stock based in?

ProSomnus Common Stock is headquartered in United States

When did ProSomnus Common Stock go public?

ProSomnus Common Stock's initial public offering (IPO) was on 28 July 2021

Is ProSomnus Common Stock in the S&P 500?

No, ProSomnus Common Stock is not included in the S&P 500 index

Is ProSomnus Common Stock in the NASDAQ 100?

No, ProSomnus Common Stock is not included in the NASDAQ 100 index

Is ProSomnus Common Stock in the Dow Jones?

No, ProSomnus Common Stock is not included in the Dow Jones index

When was ProSomnus Common Stock's last earnings report?

ProSomnus Common Stock's most recent earnings report was on 14 November 2024

When does ProSomnus Common Stock report earnings?

The date for ProSomnus Common Stock's next earnings report has not been announced yet

Should I buy ProSomnus Common Stock stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions